A Journey with Total Human Eye Allotransplantation: Vision Restoration for the Future

Kia M. Washington, MD, FACS

Professor

Department of Surgery

Division of Plastic Surgery

Department of Ophthalmology

CU Anschutz School of Medicine

Learning Objectives

At the conclusion of this presentation, participants should be able to understand:

• Understanding the barriers to making Total Human Eye Allotransplantation a clinical reality.
• Learning about new innovations on the horizon to make Total Human Eye Allotransplantation a clinical reality.
• Learning about the progress that has been made towards Total Human Eye Allotransplantation.

Dr. Subramanian reports financial relationship as a consultant for ACELYRIN, Alexion Pharma, Amgen, GenSight Biologics, Invex Therapeutics, Kriya Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, an investigator for Amgen, GenSight Biologics, Immunovant, Invex Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, recipient of a research grant from Amgen and a DSMB member for Argenx. All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of AMA PRA Category 1.5 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.